India's pharma sector is witnessing notable activity in drug and approval, with important updates emerging around market. The Drug Approvals section provides a curated, regularly updated overview of developments that matter to professionals across the value chain.
Sources in this section include RAPS.org, MedPage Today, and The Jerusalem Post. The coverage spans regulatory updates, corporate news, and research findings — providing professionals with a well-rounded perspective on current developments in drug and adjacent areas.
Key reference resources include CDSCO Drug Approvals for official guidelines and US FDA Drug Approvals for industry intelligence. Those tracking the science underpinning these developments will find WHO Prequalification Programme a reliable resource for peer-reviewed evidence and data.
Showing 30 articles
-
This Week at FDA: WH reviewing candidates for FDA commissioner, Diamantas’ rare disease outreach, and more
This Week at FDA: WH reviewing candidates for FDA commissioner, Diamantas’ rare disease outreach, and more RAPS.org
-
What Virus Now Faces a New FDA Approval?
What Virus Now Faces a New FDA Approval? MedPage Today
-
Trump claims unnamed drug can bring people back from death, boasts success of Right To Try Act
Trump claims unnamed drug can bring people back from death, boasts success of Right To Try Act The Jerusalem Post
-
Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally
Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally TradingView
-
Where do Europeans wait longest for new medicines?
Where do Europeans wait longest for new medicines? MSN
-
Mounjaro (Tirzepatide): Side Effects, Risks & FDA Warnings
Mounjaro (Tirzepatide): Side Effects, Risks & FDA Warnings Drugwatch.com
-
Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth
Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth Business Standard
-
데일리팜코리아, 데일리팜 영문뉴스, dailypharmkorea
데일리팜코리아, 데일리팜 영문뉴스, dailypharmkorea 데일리팜
-
데일리팜코리아, 데일리팜 영문뉴스, dailypharmkorea
데일리팜코리아, 데일리팜 영문뉴스, dailypharmkorea 데일리팜
-
Newspoint: Khorakiwala’s antibiotic bet
Newspoint: Khorakiwala’s antibiotic bet financialexpress.com
-
A clinical trial shows a pill almost doubled survival for pancreatic cancer patients. Now what?
A clinical trial shows a pill almost doubled survival for pancreatic cancer patients. Now what? PolitiFact
-
Breaking !! CMS Hemp Program Appeal Filed in Federal Appellate Court
Breaking !! CMS Hemp Program Appeal Filed in Federal Appellate Court Newswire.com
-
Improved Prescription Drug Safety Doesn’t Need to Come at the Cost of the Pharmaceutical Sector
Improved Prescription Drug Safety Doesn’t Need to Come at the Cost of the Pharmaceutical Sector National Taxpayers Union
-
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia Business Wire
-
Groundbreaking New Drug Nearly Doubles Pancreatic Cancer Survival
Groundbreaking New Drug Nearly Doubles Pancreatic Cancer Survival AOL.com
-
4 Biotech Stocks Investors Should Watch in 2026
4 Biotech Stocks Investors Should Watch in 2026 TradingView
-
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval PR Newswire
-
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. markets.businessinsider.com
-
Depression study: IV ketamine patients remitted more than nasal esketamine
Depression study: IV ketamine patients remitted more than nasal esketamine Stock Titan
-
Alembic Pharma Bags USFDA Approval for Generic Haldol Tablets, Targets USD 27 Million Market
Alembic Pharma Bags USFDA Approval for Generic Haldol Tablets, Targets USD 27 Million Market Medical Dialogues
-
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market Macau Business
-
Secretary for Health concludes visit to Fujian (with photos)
Secretary for Health concludes visit to Fujian (with photos) info.gov.hk
-
Alembic Pharmaceuticals in Focus After Receiving USFDA Approval For Drug With $27 Million Market Opportunity
Alembic Pharmaceuticals in Focus After Receiving USFDA Approval For Drug With $27 Million Market Opportunity Trade Brains
-
DH invites representatives from GBA Center for Drug Evaluation and Inspection of National Medical Products Administration to brief local pharmaceutical industry on latest developments in drug regulation and registration evaluation in Chinese Mainland (with
DH invites representatives from GBA Center for Drug Evaluation and Inspection of National Medical Products Administration to brief local pharmaceutical industry on latest developments in drug regulation and registration evaluation in Chinese Mainland (with info.gov.hk
-
Aurobindo Pharma Secures USFDA Approval for Tofacitinib Tablets
Aurobindo Pharma Secures USFDA Approval for Tofacitinib Tablets Siliconindia
-
Hyderabad-based Aurobindo Pharma gets US FDA nod for arthritis and colitis drug, eyes $494 million market
Hyderabad-based Aurobindo Pharma gets US FDA nod for arthritis and colitis drug, eyes $494 million market financialexpress.com
-
Alembic Pharma gets USFDA nod for Haloperidol tablets; addresses $27 million market
Alembic Pharma gets USFDA nod for Haloperidol tablets; addresses $27 million market CNBC TV18
-
FDA to review AI tool that predicts drug‑induced liver injury, a leading cause of trial failures
FDA to review AI tool that predicts drug‑induced liver injury, a leading cause of trial failures Новости GxP
-
MFDS rejects Genexine's Efesa application, company plans resubmission
MFDS rejects Genexine's Efesa application, company plans resubmission koreabiomed.com
-
Otsuka's Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
Otsuka's Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval IndiaMedToday